Kosmos is designed to offer diagnostic-quality heart, lung, and abdominal scans in a handheld tool
Kosmos AI-assisted hand-held tool. (Credit: PRNewswire / EchoNous Inc)
EchoNous has secured $60m in funding from Kennedy Lewis Investment Management for its Kosmos artificial intelligence (AI) guided point-of-care ultrasound (POCUS) system.
The company will use the funding to boost the commercial introduction of the Kosmos device.
The investment from Kennedy Lewis includes senior secured debt and equity. KKR has been EchoNous’ principal investor since 2015.
Kosmos is claimed to be the first AI-guided POCUS system to deliver diagnostic-quality imaging, similar to those provided by larger, less portable and expensive imaging machines.
The device, which facilitates systolic heart function assessment, is said to be the only handheld POCUS device to provide continuous-wave Doppler capability, a feature with significant applications for cardiology.
According to the company, the system is also the only product of its size to meet HIPAA requirements for data collection, storage, and transmission.
EchoNous CEO Kevin Goodwin said: “This investment marks a turn toward an exciting future for POCUS in which clinical bedside medicine is driven by higher-performance ultrasound technologies that are easy to implement and cost-effective.
“To make this vision a reality, we value experienced partners who can see that future as clearly as we do. We could not be happier to have Kennedy Lewis’ support.”
Established in 2016, EchoNous is involved in the development of intelligent POCUS tools.
The company’s Kosmos device delivers diagnostic-quality heart, lung, and abdominal scans in a handheld tool.
The device provides ultrasound, ECG, colour pulsed-wave and continuous-wave Doppler capabilities. It also serves as a digital stethoscope and offers AI-guided cardiac scanning.